treated previously patients ixazomib therapy eligible prior subjects study chemotherapy 
bevacizumab prior treatment patients therapy received weeks treated previously regimen 
ibrutinib prior treatment therapy btk exposure investigational inhibitors previously patients 
avastin bevacizumab received prior weeks treatment therapy use scheduled planned